Drug Information

Drug General Information
Drug ID
D0U4VT
Former ID
DAP001265
Drug Name
Trimethadione
Synonyms
Absentol; Absetil; Convenixa; Convexina; Edion; Epidione; Epidone; Epixal; Etydion; Minoaleuiatin; Minoaleviatin; Petidion; Petidon; Petilep; Petimalin; Pitmal; Ptimal; Tioxanona; Tredione; Tricione; Tridilona; Tridion; Tridione; Tridone; Trilidona; Trimedal; Trimedone; Trimetadiona; Trimetadione; Trimethadion; Trimethadionum; Trimethdione; Trimethin; Trimethinum; Trimetin; Trioksal; Trioxanona; Triozanona; Tromedone; Troxidone; Abbott Brand of Trimethadione; Trimetadione [DCIT]; A 2297; Mino-Aleviatin; Neo-Absentol; Tridione (TN); Trimetadiona [INN-Spanish]; Trimethadione [INN:JAN]; Trimethadionum [INN-Latin]; Trimethadione (JP15/INN); 3,3,5-Trimethyl-2,4-diketooxazolidine; 3,5,5,-Trimethyloxazolidine-2,4-dione; 3,5,5-TRIMETHYL-OXAZOLIDINE-2,4-DIONE; 3,5,5-Trimethyl-1,3-oxazolidine-2,4-dione; 3,5,5-Trimethyl-2,4-oxazolidinedione; 3,5,5-Trojmetylooksazolidyno-2,4-dion; 3,5,5-Trojmetylooksazolidyno-2,4-dion [Polish]
Drug Type
Small molecular drug
Indication Epileptic conditions; Pancreatic cancer [ICD9: 345, 140-199, 140-229, 157, 210-229; ICD10:G40, C25] Approved [538387], [542339], [551871]
Therapeutic Class
Anticonvulsants
Structure
Download
2D MOL

3D MOL
Formula
C6H9NO3
InChI
InChI=1S/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3
InChIKey
IRYJRGCIQBGHIV-UHFFFAOYSA-N
CAS Number
CAS 127-48-0
PubChem Compound ID
5576
PubChem Substance ID
79578, 442280, 3140648, 4752043, 7847458, 8153431, 10321761, 10506232, 11112276, 11466543, 11467663, 11486126, 12075302, 14793827, 24899914, 29224614, 46504478, 47515477, 47589147, 47810920, 48334662, 48414586, 48416668, 49640650, 49698533, 49857709, 50100405, 50451607, 57322853, 57654646, 87688533, 92125435, 92307900, 92729771, 103193092, 103914246, 104309629, 117476493, 118232715, 121363106, 124801142, 124882159, 125563380, 126562866, 127307220, 127307221, 127307222, 127307223, 127307224, 127307225
SuperDrug ATC ID
N03AC02
SuperDrug CAS ID
cas=000127480
Target and Pathway
Target(s) Voltage-dependent T-type calcium channel alpha-1G subunit Target Info Blocker [536353]
KEGG Pathway MAPK signaling pathway
Calcium signaling pathway
Circadian entrainment
Type II diabetes mellitus
PANTHER Pathway Endogenous cannabinoid signaling
GABA-B receptor II signaling
Nicotine pharmacodynamics pathway
Pathway Interaction Database Regulation of nuclear beta catenin signaling and target gene transcription
PathWhiz Pathway Muscle/Heart Contraction
Reactome NCAM1 interactions
WikiPathways NCAM signaling for neurite out-growth
Nicotine Activity on Chromaffin Cells
References
Ref 538387FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 005856.
Ref 542339(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7316).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 536353Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60. Epub 2006 Dec 31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.